ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2022
Safety of Peptide Receptor Radionuclide Therapy with
Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 18 citations in OpenAlex.
- Comparative assessment of KDIGO and CTCAE criteria for detecting renal function deterioration after peptide receptor radionuclide therapy.European journal of nuclear medicine and molecular imaging · 2026Article
- Dual‑targeted radioligand therapy with [European journal of nuclear medicine and molecular imaging · 2026Article
- Clinical research analysis of [European journal of nuclear medicine and molecular imaging · 2026Article
- [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- Sex-dependent PRRT toxicity in patients with metastatic somatostatin receptor-avid neuroendocrine tumors treated withHormones (Athens, Greece) · 2026Article
- PRRT for well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs).Endocrine-related cancer · 2026Review
- Global insights into [Scientific reports · 2026Article
- Complications and outcomes of radioligand therapy in patients with neuroendocrine neoplasms depending on the baseline glomerular filtration rate.European journal of nuclear medicine and molecular imaging · 2025Article
- Sequencing Choices and Real-World Clinical Management in Advanced Grade 2/3 GEP-NET Treatment: The Emerging Role of PRRT.Cancers · 2025Review
- Predictors of renal function decline in patients with gastroenteropancreatic neuroendocrine tumors undergoing [177Lu]Lu-DOTA-TATE therapy.EJNMMI research · 2025Article
- Emerging innovations in theranostics for pancreatic neuroendocrine tumors.NPJ precision oncology · 2025Review
- Safety, pharmacokinetics, and dosimetry ofActa pharmaceutica Sinica. B · 2025Article
- Estimation of kidney doses from [EJNMMI physics · 2024Article
- Radionuclide Theranostics in Neuroendocrine Neoplasms: An Update.Current oncology reports · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Our purpose was to assess the efficacy and safety of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.